Ultragenyx Settles DOJOLVI Patent Litigation With Navinta, Allowing Generic Entry Starting January 1, 2033; Or July 2033 With Pediatric Exclusivity; Similar Patent Litigation Against Other DOJOLVI Abbreviated New Drug Application Filers Related To...
